This afternoon at our GHRU AGM, we’re diving into challenges and opportunities of structured surveys through a World Café format. From communicating results beyond journals to measuring impact, colleagues from across the GHRU network are exchanging insights and solutions that

Kicking off Day 2 of #GHRU2025 in Bohol 🇵🇭 with a focus on structured surveys. Our @NIHRresearch-funded Global Health Research Unit teams are sharing updates on the KlebSurvey and developing rapid reports to support public health decision-making.

Our @NIHRresearch funded GHRU together in Bohol, Philippines. Colleagues from Colombia, India, Nigeria, the Philippines & the UK working together to strengthen genomic surveillance of AMR at the Unit’s annual general meeting. 🌍🤝🧬

We’re in the Philippines 🇵🇭 this week for the 6th NIHR Global Health Research Unit Annual Meeting on Genomic Surveillance of AMR. Hosted by our partners at @RITMPH, teams from across the GHRU network are sharing progress and planning for the future.

Future planned updates include a) incorporation and filtering of additional metadata (e.g. isolate source), b) adding the ability to display data from bespoke genome collections (including user-defined) and c) extending to additional pathogens/vaccine targets.

https://t.co/TlO2nswEUA currently displays data for >100k high-quality genomes with geotemporal sampling information (post-2010), but we demonstrate that substantial biases and geographic gaps remain in the coverage of available genomes.

With analytics powered by https://t.co/9tU5gFcsRR, the platform uses the same “always-on” pipeline as the sister tool, https://t.co/VzWkTCzoqI, with new genomes assembled, analysed and incorporated on an ongoing basis (every 4h) as public data are newly deposited.

Users can assess vaccine target types (e.g. serotypes) within a broader population context by exploring their relationships with associated variant types (e.g. STs) and AMR markers, and within the context of existing pneumococcal vaccine formulations.

We’ve initially focused on showing data for existing/prospective multivalent polysaccharide-based vaccines for Streptococcus pneumoniae, Klebsiella pneumoniae (and related species) and Acinetobacter baumannii.

As global representativeness of data grows from increased genomic surveillance, we have designed https://t.co/TlO2nswEUA to support different stages of the vaccine pipeline, although caution in interpretation is currently important due to data representativeness (see below).

Pleased to share our new preprint describing https://t.co/SHQ7a2yFUq, an interactive platform enabling exploration of vaccine target diversity from global genome data: https://t.co/p72GCpCfBq

By combining survey data with additional public data, we also found substantial global spread of high-risk E. coli clones with NDM-5 and other carbapenemases. We found many introductions of these into European hospitals in 2019, albeit with limited onward nosocomial transmission.

Our findings suggest that the situation with carbapenem-resistant K. pneumoniae has continued to worsen and that control measures have not been able to interrupt transmission of high-risk lineages circulating within European hospital networks.

Special thanks also to the project leads and collaborators @ECDC_EU and Public Health Agency of Sweden, especially Anke Kohlenberg, Alma Brolund and Inga Froding, with whom it has been a pleasure to work with and learn from over the many years spanning the project.

The work comes together from the valiant efforts of all participating hospitals and reference laboratories, forming the EURGen-Net CCRE Survey Working Group, who continued with the data collection despite onset of the COVID-19 pandemic shortly after the survey period.

The manuscripts, which follow up on the 2013-14 EuSCAPE survey, describe the occurrence and spread of carbapenem-resistant K. pneumoniae and E. coli using epidemiological, microbiological and WGS data obtained for isolates from >300 hospitals.

We’re pleased to share two new preprints with results from a structured survey of carbapenem- and/or colistin-resistant Enterobacterales (CCRE), conducted in 37 European countries in 2019. E. coli: https://t.co/mlh3IV8G5E K. pneumoniae: https://t.co/zmFxFfhr2N @ECDC_EU

Huge disparity in genomic data: We support all efforts to increase the genomic surveillance of pathogens on a global scale as dynamics differ locally: what happens in one place does not translate to another and high-risk clones can emerge anywhere. https://t.co/s1977Z86RJ can be

Always-on: all QC’d genomes with geotemporal metadata, are ingested from archives, analysed in https://t.co/EHcyaJQPwc and results visualised within https://t.co/s1977Z86RJ. Data are extracted and updated every 4h, with observed trends therefore only delayed by time to genome

We show disparities between high- and low- income settings, indicate vast gaps in our knowledge globally and highlight the need for ongoing,structured surveillance combined with timely data deposition (including metadata) to support public health